Latest Fairmount Funds Management LLC Stock Portfolio
Fairmount Funds Management LLC Performance:
2025 Q2: 0.89%YTD: -2.81%2024: 9.94%
Performance for 2025 Q2 is 0.89%, and YTD is -2.81%, and 2024 is 9.94%.
About Fairmount Funds Management LLC and 13F Hedge Fund Stock Holdings
In it's latest 13F Holdings report, Fairmount Funds Management LLC reported an equity portfolio of $771.9 Millions as of 30 Jun, 2025.
The top stock holdings of Fairmount Funds Management LLC are , AXSM, . The fund has invested 11.5% of it's portfolio in APOGEE THERAPEUTICS INC and 11% of portfolio in AXSOME THERAPEUTICS INC.
The fund managers got completely rid off BICARA THERAPEUTICS INC stocks. Fairmount Funds Management LLC opened new stock positions in JADE BIOSCIENCES INC (AVTE), CRESCENT BIOPHARMA INC. and CYTOMX THERAPEUTICS INC (CTMX). The fund showed a lot of confidence in some stocks as they added substantially to KINIKSA PHARMACEUTICALS INTL, SCHOLAR ROCK HLDG CORP (SRRK) and VIRIDIAN THERAPEUTICS INC (VRDN).
The top stock holdings of Fairmount Funds Management LLC are , AXSM, . The fund has invested 11.5% of it's portfolio in APOGEE THERAPEUTICS INC and 11% of portfolio in AXSOME THERAPEUTICS INC.
The fund managers got completely rid off BICARA THERAPEUTICS INC stocks. Fairmount Funds Management LLC opened new stock positions in JADE BIOSCIENCES INC (AVTE), CRESCENT BIOPHARMA INC. and CYTOMX THERAPEUTICS INC (CTMX). The fund showed a lot of confidence in some stocks as they added substantially to KINIKSA PHARMACEUTICALS INTL, SCHOLAR ROCK HLDG CORP (SRRK) and VIRIDIAN THERAPEUTICS INC (VRDN).
Fairmount Funds Management LLC Annual Return Estimates Vs S&P 500
Our best estimate is that Fairmount Funds Management LLC made a return of 0.89% in the last quarter. In trailing 12 months, it's portfolio return was 1.59%.
New Buys
| Ticker | $ Bought |
|---|---|
| jade biosciences inc | 32,171,500 |
| crescent biopharma inc. | 22,400,200 |
| cytomx therapeutics inc | 8,845,240 |
New stocks bought by Fairmount Funds Management LLC
Additions
| Ticker | % Inc. |
|---|---|
| kiniksa pharmaceuticals intl | 60.84 |
| scholar rock hldg corp | 32.75 |
| enliven therapeutics inc | 15.88 |
| viridian therapeutics inc | 0.41 |
| dianthus therapeutics inc | 0.24 |
Additions to existing portfolio by Fairmount Funds Management LLC
Reductions
Sold off
| Ticker | $ Sold |
|---|---|
| bicara therapeutics inc | -10,217,700 |
Fairmount Funds Management LLC got rid off the above stocks
Sector Distribution
Fairmount Funds Management LLC has about 55.8% of it's holdings in Healthcare sector.
| Sector | % |
|---|---|
| Healthcare | 55.8 |
| Others | 44.2 |
Market Cap. Distribution
Fairmount Funds Management LLC has about 0% of it's portfolio invested in the large-cap and mega-cap stocks.
| Category | % |
|---|---|
| UNALLOCATED | 44.2 |
| SMALL-CAP | 30.7 |
| MID-CAP | 18.2 |
| NANO-CAP | 5.7 |
| MICRO-CAP | 1.1 |
Stocks belong to which Index?
About 45.3% of the stocks held by Fairmount Funds Management LLC either belong to S&P 500 or RUSSELL 2000 index.
| Index | % |
|---|---|
| Others | 54.7 |
| RUSSELL 2000 | 45.3 |
Fairmount Funds Management LLC Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of Fairmount Funds Management LLC
Fairmount Funds Management LLC has 17 stocks in it's portfolio. About 80.5% of the portfolio is in top 10 stocks. AXSM proved to be the most loss making stock for the portfolio. COGT was the most profitable stock for Fairmount Funds Management LLC last quarter.
Last Reported on: 14 Aug, 2025| Ticker | Namesorted descending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| apogee therapeutics inc | 11.53 | 2,048,650 | 88,972,700 | unchanged | 0.00 | |||
| AXSM | axsome therapeutics inc | 11.02 | 815,176 | 85,096,200 | unchanged | 0.00 | ||
| enliven therapeutics inc | 9.64 | 3,711,440 | 74,451,600 | added | 15.88 | |||
| SRRK | scholar rock hldg corp | 8.37 | 1,824,030 | 64,607,200 | added | 32.75 | ||
| AGLE | spyre therapeutics inc | 7.79 | 4,018,100 | 60,151,000 | unchanged | 0.00 | ||
| NUVL | nuvalent inc | 7.19 | 727,563 | 55,513,100 | unchanged | 0.00 | ||
| dianthus therapeutics inc | 6.53 | 2,707,190 | 50,435,000 | added | 0.24 | |||
| kiniksa pharmaceuticals intl | 6.36 | 1,772,840 | 49,054,500 | added | 60.84 | |||
| VRDN | viridian therapeutics inc | 6.27 | 3,459,910 | 48,369,600 | added | 0.41 | ||
| COGT | cogent biosciences inc | 5.79 | 6,225,640 | 44,700,100 | unchanged | 0.00 | ||
| oruka therapeutics inc | 4.90 | 3,371,920 | 37,799,200 | unchanged | 0.00 | |||
| AVTE | jade biosciences inc | 4.17 | 3,220,370 | 32,171,500 | new | |||
| crescent biopharma inc. | 2.90 | 1,387,870 | 22,400,200 | new | ||||
| ATXS | astria therapeutics inc | 2.47 | 3,554,130 | 19,050,100 | unchanged | 0.00 | ||
| zenas biopharma inc | 2.38 | 1,892,810 | 18,341,300 | unchanged | 0.00 | |||
| IKT | inhibikase therapeutics inc | 1.55 | 6,125,000 | 11,943,800 | unchanged | 0.00 | ||
| CTMX | cytomx therapeutics inc | 1.15 | 3,896,580 | 8,845,240 | new | |||
| bicara therapeutics inc | 0.00 | 0.00 | 0.00 | sold off | -100 | |||
